Targeted Oncology

🖥️Real Patient Cases Brought to You Virtually Experts in our Virtual Tumor Board series review real patient cases and inform you on the diagnosis, biomarker testing, and treatment strategies involved. 👉Watch Now: hubs.li/Q03YBNL90

📢 BREAKING: The #FDA has approved atezolizumab for the adjuvant treatment of muscle invasive #BladderCancer with ctDNA molecular residual disease after cystectomy. Read more: targetedonc.com/view/fda-appro… #FDANews #MIBC

CAR T is starting to move beyond academic centers, but insurance, cost and policy gaps keep most eligible patients from receiving it. 🩺 🎥 In our May Community Corner episode, Dr @michaelwangmd (@UTMDAnderson) describes the systemic nature of these gaps: targetedonc.com/view/dr-wang-o…

🔬 UGN-103 (mitomycin) for intravesical solution sustained disease control through 6 months in the UTOPIA trial in recurrent intermediate-risk low-grade #NMIBC, supporting a future NDA. Read more: targetedonc.com/view/ugn-103-s… #BladderCancer #UrologicOncology #ClinicalResearch

🔬 Gedatolisib moves frontline in HR+/HER2– metastatic #BreastCancer in the phase 3 VIKTORIA-2 trial, adding endocrine-sensitive patients and testing triplets vs ribociclib to boost PFS. Read more: targetedonc.com/view/viktoria-… #Oncology #ClinicalTrials #ClinicalResearch

🔎 FDA News: The #FDA has granted suplexa, a non-engineered autologous cellular #immunotherapy, fast track designation for patients with MSI-H #ColorectalCancer. Read more: targetedonc.com/view/fda-grant… #Oncology #GIOnc

💬 In an interview, Dr Rawan Faramand (@MoffittNews) discussed her research on cost-effectiveness of graft modification to prevent #GVHD in hematopoietic cell transplant. Read the full interview: targetedonc.com/view/cost-anal…

🔬 The phase 3 VOLGA trial showed perioperative durvalumab plus neoadjuvant enfortumab vedotin reduced the risk of death in muscle-invasive #BladderCancer. Read more: targetedonc.com/view/periopera… #UrologicOncology #MIBC #ClinicalTrials

A new @OSUCCC_James program for young patients with #cancer breaks disease silos, showing how multidisciplinary teamwork improves coordination, insights, and care. 🎥 Learn about the program's implementation with OSU's Dr Rathmell in an interview: targetedonc.com/view/lessons-i…

Dr Rawan Faramand (@MoffittNews) discusses how reducing the cost of #GVHD therapy could benefit health systems. 🩺💵 🎥 WATCH: targetedonc.com/view/reduced-g…

🔬 Mitomycin for intravesical solution demonstrated durable responses in patients with recurrent low-grade intermediate-risk non–muscle-invasive #BladderCancer in 36-month follow-up data from the phase 3 ENVISION trial. Read more: targetedonc.com/view/mitomycin… #NMIBC #ClinicalTrials

📢 BREAKING: Sonrotoclax has gained #FDA approval as a promising treatment for relapsed mantle cell #lymphoma, showcasing strong efficacy and safety in clinical trials. Read more: targetedonc.com/view/fda-appro… #FDANews #Hematology #Oncology #HemeOnc

📢 BREAKING: The #FDA has approved an all-oral treatment for newly diagnosed acute myeloid #leukemia, enhancing options for patients ineligible for intensive chemotherapy. Read more: targetedonc.com/view/fda-appro… #FDANews #AML #Hematology #HemeOnc

🔬 Gene editing donor cells enabled less toxic targeted maintenance post- #transplant, according to data from the NEO-CYT study published in @NatureMedicine. The study was not continued for fiscal reasons; poster to be presented at #ASCO26. Read more: targetedonc.com/view/cd33-dele…

🔬 The NEO-CYT trial has begun treating patients with #melanoma in the perioperative setting, combining a novel agent with immune checkpoint inhibitor therapy. Read more: targetedonc.com/view/first-pat… #ClinicalResearch #ClinicalTrials #Oncology

🔬 Sexual activity/desire and physical function were improved by TRT in men with hypogonadism post-prostatectomy, according to results from the SPIRIT trial published in @JAMAInternalMed. Read more: targetedonc.com/view/sexual-ph… #ProstateCancer #ClinicalResearch

Dr Rawan Faramand (@MoffittNews) explains how a cost analysis supported Orca-T engineered graft by reducing the need for #GVHD therapy vs standard prophylaxis in a recent interview. 🎥 WATCH: targetedonc.com/view/cost-effe…

🔎 FDA News: The #FDA has granted breakthrough therapy designation to ADC emiltatug ledadotin for treatment of locally advanced, recurrent or metastatic adenoid cystic carcinoma (ACC) with solid histology or high-grade transformation. Read more: targetedonc.com/view/fda-grant…

💬 In a recent interview, Andrzej Jakubowiak (@UChicagoHemOnc) explained promising results for KRd maintenance and the potential of modifying the posttransplant maintenance paradigm in multiple #myeloma. Read the full interview: targetedonc.com/view/atlas-tri…

What if exercise were treated like any other evidence-based #oncology intervention? 🏃‍♂️ In this video, 3 experts from @umiamimedicine @OSUCCC_James discuss the critical role exercise plays in improving outcomes in patients with #cancer. 🎥 Watch now: targetedonc.com/view/the-exerc…